DOCSLIB.ORG

First Two Unrelated Cases of Isolated Sedoheptulokinase Deficiency: a Benign Disorder?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
First Two Unrelated Cases of Isolated Sedoheptulokinase Deficiency: a Benign Disorder? J Inherit Metab Dis (2015) 38:889–894 DOI 10.1007/s10545-014-9809-1 ORIGINAL ARTICLE First two unrelated cases of isolated sedoheptulokinase deficiency: A benign disorder? Mirjam M. C. Wamelink & RubenJ.J.F.Ramos& Annette P. M. van den Elzen & George J. G. Ruijter & Ramon Bonte & Luisa Diogo & Paula Garcia & Nelson Neves & Benjamin Nota & Arvand Haschemi & Isabel Tavares de Almeida & Gajja S. Salomons Received: 23 August 2014 /Revised: 29 December 2014 /Accepted: 30 December 2014 /Published online: 3 February 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract We present the first two reported unrelated patients causal factor for the clinical phenotypes of our patients. This with an isolated sedoheptulokinase (SHPK) deficiency. The study illustrates the necessity of extensive functional and clin- first patient presented with neonatal cholestasis, hypoglyce- ical workup for interpreting a novel variant, including non- mia, and anemia, while the second patient presented with con- sense variants. genital arthrogryposis multiplex, multiple contractures, and dysmorphisms. Both patients had elevated excretion of erythritol and sedoheptulose, and each had a homozygous Introduction nonsense mutation in SHPK.SHPKisanenzymethatphos- phorylates sedoheptulose to sedoheptulose-7-phosphate, Sedoheptulokinase (SHPK; EC 2.7.1.14), formerly known as which is an important intermediate of the pentose phosphate carbohydrate-kinase-like (CARKL), is an enzyme that phos- pathway. It is questionable whether SHPK deficiency is a phorylates sedoheptulose to sedoheptulose-7-phosphate (sedoheptulose-7P) (Touchman et al 2000; Wamelink et al 2008; Kardon et al 2008; Haschemi et al 2012). SHPK is Communicated by: K. Michael Gibson highly expressed in liver, kidney, pancreas, and heart tissue. Electronic supplementary material The online version of this article Sedoheptulose-7P is an important intermediate of the pentose (doi:10.1007/s10545-014-9809-1) contains supplementary material, which is available to authorized users. phosphate pathway (PPP), a key pathway of carbohydrate metabolism. The PPP and glycolysis are tightly connected: * : : M. M. C. Wamelink ( ) B. Nota G. S. Salomons The PPP is located in the cytosol and is primarily responsible Department of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center, De Boelelaan 1117, for the production of cytosolic nicotinamide adenine dinucle- 1081HV Amsterdam, The Netherlands otide phosphate, reduced (NADPH) and ribose-5P. The SHPK e-mail: [email protected] protein co-localizes with glucose-6P dehydrogenase in the cytoplasm (Haschemi et al 2012). SHPK seems to be an im- R. J. J. F. Ramos : I. Tavares de Almeida Metabolism & Genetics, iMed.UL, Fac. Pharmacy- Univ. of Lisboa, portant regulatory enzyme, being responsible for feeding Lisboa, Portugal sedoheptulose-7P molecules to the PPP independently of glu- cose. Effectively, this allows the reversible function of A. P. M. van den Elzen transaldolase (TALDO) and/or transketolase when glyceralde- Department of Paediatrics, Reinier de Graaf Gasthuis Delft, Delft, The Netherlands hyde-3-phosphate, arising from the glycolytic pathway, is : used by the PPP, when increased amounts of NADPH and/or G. J. G. Ruijter R. Bonte ribose moieties are needed for nucleotide production Department of Clinical Genetics, Erasmus Medical Center, (Wamelink et al 2008; Nagy and Haschemi 2013). Free Rotterdam, The Netherlands sedoheptulose can be either derived dietarily from fruits and : : L. Diogo P. Garcia N. Neves vegetables (Kardon et al 2008) or formed enzymatically by Paediatric Hospital of Coimbra, Coimbra, Portugal dephosphorylation from sedoheptulose-7P or possibly from other heptoses, such as mannoheptulose or 7-O-galloyl- A. Haschemi Department of Laboratory Medicine, Medical University of Vienna, sedoheptulose. To date, no specific sedoheptulose-7P phos- Vienna, Austria phatase has been reported. 890 J Inherit Metab Dis (2015) 38:889–894 Knockdown of SHPK in a mouse macrophage cell line creatinine 132 μmol/L and urea 11 mmol/L at day 5 of life, resulted in increased glyceraldehyde-3P, xylulose-5P, and which normalized on day 10). He has chronic diarrhea, with ribose-5P intracellular levels. Sedoheptulose concentrations steatorrhea and severe growth retardation including short stat- were not notably changed, while sedoheptulose-7P was sig- ure and macrocephaly (relative to stature). Frequent, mostly nificantly decreased (Haschemi et al 2012), which resulted in asymptomatic, short-fasting hypoglycemic episodes (with rerouting of glucose from aerobic to anaerobic metabolism normal lactate and ketones) and postprandial hyperglycemia and was accompanied by a decreased nicotinamide adenine aggravated by the end of the first year of life persist in spite of dinucleotide (NAD)/NADH ratio. In the same cell line, the frequent meals. Transient hypocortisolism was identified, but opposite was found by overexpressed SHPK, although hypoglycemia did not respond to specific treatment. He is sedoheptulose-7P concentrations remained normal. In a currently under exocrine pancreatic yeast supplementation. screen for new regulators of macrophage activation, over- He has moderate intellectual disability and neurosensorial expression of SHPK was found to block lipopolysaccha- deafness. He needed several blood transfusions due to chronic ride (LPS)-induced tumor necrosis factor alpha (TNFα) microcytic hypochromic anemia, with normal ferritin, secretion by these cells (Haschemi et al 2012). In vitro leucocytes, and platelets. Because of childhood infections and in vivo, SHPK transcript is endogenously downregu- (bronchiolitis and middle ear infections with febrile lated in mice and humans during LPS-induced inflamma- rhinopharyngitis), inpatient admission was needed due to dif- tion. In vitro, knockdown of the gene by micro-RNA- ficulty in glycemic control; immune system deficiency was adapted short hairpin RNA (shRNA-mir) results in mild ruled out. His abdominal skin is strikingly thin, with upper activation of macrophages. This indicates that SHPK- collateral circulation and diastasis recti without liver or spleen dependent metabolic reprogramming is required for proper enlargement. M1- and M2-like macrophage polarization and is a rate- Brain magnetic resonance imaging (MRI) was normal in limiting requirement for appropriate glucose flux during the neonatal period. At the age of 3 years, MRI showed ven- macrophage polarization (Haschemi et al 2012). tricular enlargement, cerebral subcortical atrophy, hyperin- So far, SHPK deficiency has not been described in humans tense periventricular lesions, hypomyelinization, and a as an isolated defect and is only known as a combined defect, Chiari malformation type 1 (Fig. 1). with cystinosis caused by a 57-kb deletion extending from A broad etiological investigation including peroxisomal exon 10 of CTNS (cystinosin, lysosomal cystine transporter), function, carbohydrate-deficient transferrin, acylcarnitine pro- upstream through SHPK/CARKL,tointron2ofTRPV1 (tran- file, urinary organic acids, microarray comparative genomic sient receptor potential vanilloid 1) (Touchman et al 2000; hybridization (CGH) and UBR1, SBDS,andCOX412 genes Freed et al 2011). Patients with this deletion have the infantile has been inconclusive. At the age of 20 months, during a nephropathic cystinosis type (MIM 219800), but the clinical metabolic workup, elevated urinary concentrations were relevance of SHPK deficiency remains unclear. In urine of found for erythritol and sedoheptulose with gas chromatogra- these patients, high concentrations of sedoheptulose and phy mass spectrometry (GC-MS). His immune system was erythritol are detected, and in bloodspots, sedoheptulose is evaluated. Immunoglobulin (Ig) G, A, M, and E levels were also elevated compared with controls or patients with isolated normal; leucocyte number and distribution and lymphocyte cystinosis (Wamelink et al 2008, 2011). populations T, B, and NK were investigated; an inverted We diagnosed two unrelated patients with isolated SHPK CD4/CD8 and low CD19 and CD56 were found but were deficiency caused by different nonsense mutations in SHPK. not considered relevant. In the lymphoblast transformation test, there was a normal proliferative response to the mitogens phytohemagglutinin(PHA), pokeweed mitogen (PWM), and Materials and methods staphylococcal protein A (SPA). Patient 2, a girl (currently 2 years old), second child of Patients healthy consanguineous parents from Turkish heritage, was born at term. External cephalic version was successfully per- Patient 1, a boy (currently 3 years old), was born after formed antenatally because of breech presentation. She pre- 35 weeks’ gestation from a healthy Caucasian mother and sented at birth with perinatal asphyxia, birth weight of 2,580 g unknown father (suspected consanguineous relationship). (P2.3–P5), congenital arthrogryposis multiplex, hip dysplasia, The infant presented with perinatal asphyxia, birth weight of and numerous contractures. She has multiple dysmorphisms: 1,750 g (P2.3–P5), craniofacial dysmorphisms (high forehead round, asymmetrical eyes (right eye larger) with ptosis and with very large fontanels, hypotelorism, and small orbits), Bells phenomenon; small mouth; high nasal bridge; dysplastic unilateral inguinal hernia, and a sepsis-like condition with low-set ears, most prominent on the right; adducted thumbs; intestinal pseudoobstruction, transient hypoglycemia, chole- strikingly
Load more

Recommended publications
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Mitochondrial Involvement and Erythronic Acid As a Novel Biomarker in Transaldolase Deficiency Udo F.H
    Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency Udo F.H. Engelke, Fokje S.M. Zijlstra, Fanny Mochel, Vassili Valayannopoulos, Daniel Rabier, Leo A.J. Kluijtmans, András Perl, Nanda M. Verhoeven-Duif, Pascale de Lonlay, Mirjam M.C. Wamelink, et al. To cite this version: Udo F.H. Engelke, Fokje S.M. Zijlstra, Fanny Mochel, Vassili Valayannopoulos, Daniel Rabier, et al.. Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency. Biochimica et Biophysica Acta - Molecular Basis of Disease, Elsevier, 2010, 1802 (11), pp.1028. 10.1016/j.bbadis.2010.06.007. hal-00623290 HAL Id: hal-00623290 https://hal.archives-ouvertes.fr/hal-00623290 Submitted on 14 Sep 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ÔØ ÅÒÙ×Ö ÔØ Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency Udo F.H. Engelke, Fokje S.M. Zijlstra, Fanny Mochel, Vassili Valayannopou- los, Daniel Rabier, Leo A.J. Kluijtmans, Andr´asPerl, Nanda M. Verhoeven- Duif, Pascale de Lonlay, Mirjam M.C. Wamelink, Cornelis Jakobs, Eva´ Morava, Ron A. Wevers PII: S0925-4439(10)00117-1 DOI: doi: 10.1016/j.bbadis.2010.06.007 Reference: BBADIS 63115 To appear in: BBA - Molecular Basis of Disease Received date: 23 April 2010 Revised date: 11 June 2010 Accepted date: 11 June 2010 Please cite this article as: Udo F.H.
    [Show full text]
  • Protein Modification and Catabolic Fates of Lipid
    PROTEIN MODIFICATION AND CATABOLIC FATES OF LIPID PEROXIDATION PRODUCTS by CHUAN SHI Submitted in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Dissertation Advisor: Gregory P. Tochtrop, Ph.D. Department of Chemistry CASE WESTERN RESERVE UNIVERSITY January 2017 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of ______________________________________________________Chuan Shi candidate for the Doctor of Philosophy degree *. Rajesh Viswanathan (signed)_______________________________________________ (chair of the committee) Anthony Pearson ________________________________________________ Michael Zagorski ________________________________________________ Henri Brunengraber ________________________________________________ Gregory Tochtrop ________________________________________________ ________________________________________________ (date) _______________________Dec. 8, 2016 *We also certify that written approval has been obtained for any proprietary material contained therein. This thesis is dedicated to my parents in the deepest appreciation and gratitude for their unconditional love, endless support and continuous encouragement throughout every step in my life TABLE OF CONTENTS Table of Contents ................................................................................................................. i List of Figures ......................................................................................................................v List of Schemes ................................................................................................................
    [Show full text]
  • Pentose Phosphate Pathway in Health and Disease: from Metabolic
    UNIVERSIDADE DE LISBOA FACULDADE DE FARMÁCIA DEPARTAMENTO DE BIOQUÍMICA PENTOSE PHOSPHATE PATHWAY IN HEALTH AND DISEASE: FROM METABOLIC DYSFUNCTION TO BIOMARKERS Rúben José Jesus Faustino Ramos Orientador: Professora Doutora Maria Isabel Ginestal Tavares de Almeida Mestrado em Análises Clínicas 2013 Pentose Phosphate Pathway in health and disease: From metabolic dysfunction to biomarkers . Via das Pentoses Fosfato na saúde e na doença: Da disfunção metabólica aos biomarcadores Dissertação apresentada à Faculdade de Farmácia da Universidade de Lisboa para obtenção do grau de Mestre em Análises Clínicas Rúben José Jesus Faustino Ramos Lisboa 2013 Orientador: Professora Doutora Maria Isabel Ginestal Tavares de Almeida The studies presented in this thesis were performed at the Metabolism and Genetics group, iMed.UL (Research Institute for Medicines and Pharmaceutical Sciences), Faculdade de Farmácia da Universidade de Lisboa, Portugal, under the supervision of Prof. Maria Isabel Ginestal Tavares de Almeida, and in collaboration with the Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands, Dr. Mirjam Wamelink. De acordo com o disposto no ponto 1 do artigo nº 41 do Regulamento de Estudos Pós- Graduados da Universidade de Lisboa, deliberação nº 93/2006, publicada em Diário da Republica – II série nº 153 – de 5 julho de 2003, o autor desta dissertação declara que participou na conceção e execução do trabalho experimental, interpretação dos resultados obtidos e redação dos manuscritos. Para os meus pais e
    [Show full text]
  • Pentose Phosphate Pathway Biochemistry, Metabolism and Inherited Defects
    Pentose phosphate pathway biochemistry, metabolism and inherited defects Amsterdam 2008 Mirjam M.C. Wamelink The research described in this thesis was carried out at the Department of Clinical Chemistry, Metabolic Unit, VU University Medical Center, Amsterdam, The Netherlands. The publication of this thesis was financially supported by: Department of Clinical Chemistry, VU University Medical Center Amsterdam E.C. Noyons Stichting ter bevordering van de Klinische Chemie in Nederland J.E. Jurriaanse Stichting te Rotterdam Printed by: Printpartners Ipskamp BV, Enschede ISBN: 978-90-9023415-1 Cover: Representation of a pathway of sugar Copyright Mirjam Wamelink, Amsterdam, The Netherlands, 2008 2 VRIJE UNIVERSITEIT Pentose phosphate pathway biochemistry, metabolism and inherited defects ACADEMISCH PROEFSCHRIFT ter verkrijging van de graad Doctor aan de Vrije Universiteit Amsterdam, op gezag van de rector magnificus prof.dr. L.M. Bouter, in het openbaar te verdedigen ten overstaan van de promotiecommissie van de faculteit der Geneeskunde op donderdag 11 december 2008 om 13.45 uur in de aula van de universiteit, De Boelelaan 1105 door Mirjam Maria Catharina Wamelink geboren te Alkmaar 3 promotor: prof.dr.ir. C.A.J.M. Jakobs copromotor: dr. E.A. Struijs 4 Abbreviations 6PGD 6-phosphogluconate dehydrogenase ADP adenosine diphosphate ATP adenosine triphosphate CSF cerebrospinal fluid DHAP dihydroxyacetone phosphate G6PD glucose-6-phosphate dehydrogenase GA glyceraldehyde GAPDH glyceraldehyde-3-phosphate dehydrogenase GSG oxidized glutathione
    [Show full text]
  • 1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression
    SUPPLEMENTAL DATA Figure S1. Poly I:C induces IFN-β expression and signaling. Fibroblasts were incubated in media with or without Poly I:C for 24 h. RNA was isolated and processed for microarray analysis. Genes showing >2-fold up- or down-regulation compared to control fibroblasts were analyzed using Ingenuity Pathway Analysis Software (Red color, up-regulation; Green color, down-regulation). The transcripts with known gene identifiers (HUGO gene symbols) were entered into the Ingenuity Pathways Knowledge Base IPA 4.0. Each gene identifier mapped in the Ingenuity Pathways Knowledge Base was termed as a focus gene, which was overlaid into a global molecular network established from the information in the Ingenuity Pathways Knowledge Base. Each network contained a maximum of 35 focus genes. 1 Figure S2. The overlap of genes regulated by Poly I:C and by IFN. Bioinformatics analysis was conducted to generate a list of 2003 genes showing >2 fold up or down- regulation in fibroblasts treated with Poly I:C for 24 h. The overlap of this gene set with the 117 skin gene IFN Core Signature comprised of datasets of skin cells stimulated by IFN (Wong et al, 2012) was generated using Microsoft Excel. 2 Symbol Description polyIC 24h IFN 24h CXCL10 chemokine (C-X-C motif) ligand 10 129 7.14 CCL5 chemokine (C-C motif) ligand 5 118 1.12 CCL5 chemokine (C-C motif) ligand 5 115 1.01 OASL 2'-5'-oligoadenylate synthetase-like 83.3 9.52 CCL8 chemokine (C-C motif) ligand 8 78.5 3.25 IDO1 indoleamine 2,3-dioxygenase 1 76.3 3.5 IFI27 interferon, alpha-inducible
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Dema and Faust Et Al., Suppl. Material 2020.02.03
    Supplementary Materials Cyclin-dependent kinase 18 controls trafficking of aquaporin-2 and its abundance through ubiquitin ligase STUB1, which functions as an AKAP Dema Alessandro1,2¶, Dörte Faust1¶, Katina Lazarow3, Marc Wippich3, Martin Neuenschwander3, Kerstin Zühlke1, Andrea Geelhaar1, Tamara Pallien1, Eileen Hallscheidt1, Jenny Eichhorst3, Burkhard Wiesner3, Hana Černecká1, Oliver Popp1, Philipp Mertins1, Gunnar Dittmar1, Jens Peter von Kries3, Enno Klussmann1,4* ¶These authors contributed equally to this work 1Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Robert- Rössle-Strasse 10, 13125 Berlin, Germany 2current address: University of California, San Francisco, 513 Parnassus Avenue, CA 94122 USA 3Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125 Berlin, Germany 4DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Oudenarder Strasse 16, 13347 Berlin, Germany *Corresponding author Enno Klussmann Max Delbrück Center for Molecular Medicine Berlin in the Helmholtz Association (MDC) Robert-Rössle-Str. 10, 13125 Berlin Germany Tel. +49-30-9406 2596 FAX +49-30-9406 2593 E-mail: [email protected] 1 Content 1. CELL-BASED SCREENING BY AUTOMATED IMMUNOFLUORESCENCE MICROSCOPY 3 1.1 Screening plates 3 1.2 Image analysis using CellProfiler 17 1.4 Identification of siRNA affecting cell viability 18 1.7 Hits 18 2. SUPPLEMENTARY TABLE S4, FIGURES S2-S4 20 2 1. Cell-based screening by automated immunofluorescence microscopy 1.1 Screening plates Table S1. Genes targeted with the Mouse Protein Kinases siRNA sub-library. Genes are sorted by plate and well. Accessions refer to National Center for Biotechnology Information (NCBI, BLA) entries. The siRNAs were arranged on three 384-well microtitre platres.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • Supplemental Data
    Supplementary Table 1. Gene sets from Figure 6. Lists of genes from each individual gene set defined in Figure 6, including the fold-change in expression of each gene in treatment group pair-wise comparisons. ENSEMBL: Ensembl gene identifier; Symbol: official gene symbol; logFC: log fold change; p value: significance of fold-change in a pair-wise comparison, P<0.05 cut-off; FDR: false discovery rate, expected proportion of false positives among the differentially expressed genes in a pair-wise comparison (FDR<0.25 cut-off). Sup. Table 1 SET I CP versus Sal CP versus CP+DCA DCA versus Sal ENSEMBL Symbol logFC PValue FDR logFC PValue FDR logFC PValue FDR Desc ENSMUSG00000020326 Ccng1 2.64 0.00 0.00 -0.06 0.13 0.96 0.40 0.00 0.23 cyclin G1 [Source:MGI Symbol;Acc:MGI:102890] ENSMUSG00000031886 Ces2e 3.97 0.00 0.00 -0.24 0.02 0.28 0.01 1.00 1.00 carboxylesterase 2E [Source:MGI Symbol;Acc:MGI:2443170] ENSMUSG00000041959 S100a10 2.31 0.00 0.00 -0.21 0.02 0.23 -0.11 0.53 1.00 S100 calcium binding protein A10 (calpactin) [Source:MGI Symbol;Acc:MGI:1339468] ENSMUSG00000092341 Malat1 1.09 0.00 0.00 -0.11 0.20 1.00 0.66 0.00 0.00 metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) [Source:MGI Symbol;Acc:MGI:1919539] ENSMUSG00000072949 Acot1 1.73 0.00 0.00 -0.22 0.01 0.12 -0.44 0.01 1.00 acyl-CoA thioesterase 1 [Source:MGI Symbol;Acc:MGI:1349396] ENSMUSG00000064339 mt-Rnr2 1.09 0.00 0.00 -0.08 0.17 1.00 0.67 0.00 0.07 mitochondrially encoded 16S rRNA [Source:MGI Symbol;Acc:MGI:102492] ENSMUSG00000025934 Gsta3 1.86 0.00 0.00 -0.28
    [Show full text]
  • Kinome Expression Profiling to Target New Therapeutic Avenues in Multiple Myeloma
    Plasma Cell DIsorders SUPPLEMENTARY APPENDIX Kinome expression profiling to target new therapeutic avenues in multiple myeloma Hugues de Boussac, 1 Angélique Bruyer, 1 Michel Jourdan, 1 Anke Maes, 2 Nicolas Robert, 3 Claire Gourzones, 1 Laure Vincent, 4 Anja Seckinger, 5,6 Guillaume Cartron, 4,7,8 Dirk Hose, 5,6 Elke De Bruyne, 2 Alboukadel Kassambara, 1 Philippe Pasero 1 and Jérôme Moreaux 1,3,8 1IGH, CNRS, Université de Montpellier, Montpellier, France; 2Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium; 3CHU Montpellier, Laboratory for Monitoring Innovative Therapies, Department of Biologi - cal Hematology, Montpellier, France; 4CHU Montpellier, Department of Clinical Hematology, Montpellier, France; 5Medizinische Klinik und Poliklinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany; 6Nationales Centrum für Tumorerkrankungen, Heidelberg , Ger - many; 7Université de Montpellier, UMR CNRS 5235, Montpellier, France and 8 Université de Montpellier, UFR de Médecine, Montpel - lier, France ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.208306 Received: October 5, 2018. Accepted: July 5, 2019. Pre-published: July 9, 2019. Correspondence: JEROME MOREAUX - [email protected] Supplementary experiment procedures Kinome Index A list of 661 genes of kinases or kinases related have been extracted from literature9, and challenged in the HM cohort for OS prognostic values The prognostic value of each of the genes was computed using maximally selected rank test from R package MaxStat. After Benjamini Hochberg multiple testing correction a list of 104 significant prognostic genes has been extracted. This second list has then been challenged for similar prognosis value in the UAMS-TT2 validation cohort.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]